Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NIAID supports Trellis Bioscience CMV Program
The National Institute of Allergy and Infectious Disease (NIAID) will provide the $3.3m grant spread over for four years. Trellis president and CEO Stote Ellsworth said Trellis has
The National Institute of Allergy and Infectious Disease (NIAID) will provide the $3.3m grant spread over for four years. Trellis president and CEO Stote Ellsworth said Trellis has
The Phase 1 dose-ranging study of LX2931, which was designed to explore higher doses of LX2931 in patients with rheumatoid arthritis, involved 10 patients eight of whom were
According to the company, the verdict reiterates the Court’s earlier decision rendered on 29 July 2011. Myriad Genetics president and CEO Peter Meldrum said Myriad Genetics is pleased
The certification will allow WuXi to carry out non-clinical laboratory studies with respect to the requirements of the Chinese Food and Drug Act and SFDA GLP regulations. The
The EPA’s proposed plan calls for the use of a heating technology to treat six areas of contaminated soil and ground water as well as natural attenuation of
The two products use a patented delivery system, which will provide Canadian hospitals and healthcare professionals safety and cost effectiveness, according to the company. The products will be
The patients who have been diagnosed with advanced or metastatic solid tumours, including pancreatic, lung and ovarian cancers that are refractory to standard therapy, or for which no
Accelr8 which develops instruments used for the detection of pathogenic microorganisms has selected Tucson as best meeting its needs for future growth plans. Accelr8 president and CEO Lawrence
Agomelatine, a melatonergic agonist (MT1 and MT2 receptors) and 5-HT2C antagonist, is approved for the treatment of major depressive disorder in Europe, Australia and in other countries. Nectid
The company considers launching Soltamox, the FDA-approved oral liquid formulation of tamoxifen citrate, a first-line therapy for the prevention and treatment of breast cancer, later in 2012. DARA